佰仁医疗(688198) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥64,891,611.97, representing a decrease of 1.69% compared to the same period last year[7]. - Net profit attributable to shareholders for Q1 2023 was ¥11,698,274.57, down 14.03% year-over-year[7]. - The net profit after deducting non-recurring gains and losses was ¥9,016,201.18, a decline of 17.30% compared to the previous year[7]. - The net cash flow from operating activities was ¥19,517,608.89, reflecting a decrease of 15.45% year-over-year[7]. - Total operating revenue for Q1 2023 was CNY 64,891,611.97, a decrease of 1.7% compared to CNY 66,005,581.98 in Q1 2022[31]. - Net profit for Q1 2023 was CNY 11,425,536.20, down 15.8% from CNY 13,570,614.66 in Q1 2022[34]. - The company reported a profit before tax of CNY 14,133,152.54, down 13.1% from CNY 16,264,121.23 in the previous year[34]. - The total comprehensive income for the first quarter of 2023 was CNY 11,461,029.65, a decrease of 16.6% compared to CNY 13,744,523.81 in the same period of 2022[36]. - The company reported a basic and diluted earnings per share of CNY 0.09, down from CNY 0.10 in the same quarter last year[36]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,186,704,092.06, a slight increase of 0.60% from the end of the previous year[10]. - Total current assets as of March 31, 2023, amounted to ¥652,163,383.23, a decrease of 9.94% from ¥724,374,884.28 in the previous year[23]. - Cash and cash equivalents decreased to ¥98,100,152.32 from ¥128,298,513.56, representing a decline of 23.51%[23]. - Trade receivables decreased to ¥50,470,441.14 from ¥57,981,942.38, a reduction of 13.14%[23]. - Total liabilities decreased to CNY 64,265,950.94 from CNY 80,173,470.91 year-over-year, a reduction of 19.8%[30]. - Shareholders' equity increased to CNY 1,124,725,271.02, up from CNY 1,101,501,079.28, representing a growth of 2.1%[30]. - The company’s total assets amounted to CNY 1,186,704,092.06, compared to CNY 1,179,660,158.66 in the previous year, indicating a slight increase[31]. Cash Flow - The net cash flow from operating activities was CNY 19,517,608.89, down 15.5% from CNY 23,085,270.23 in Q1 2022[39]. - Cash inflow from operating activities totaled CNY 77,962,891.01, an increase of 9.5% compared to CNY 71,507,150.55 in the previous year[39]. - The cash outflow from operating activities was CNY 58,445,282.12, which increased by 20.8% from CNY 48,421,880.32 in Q1 2022[39]. - The net cash flow from investing activities was negative at CNY -48,247,368.69, compared to a positive CNY 9,898,930.07 in Q1 2022[41]. - The cash and cash equivalents at the end of the period were CNY 98,617,977.18, a decrease from CNY 185,040,249.87 at the end of Q1 2022[41]. - The cash inflow from investment activities was CNY 296,456,007.58, down from CNY 363,086,414.23 in Q1 2022[40]. - The cash outflow from investment activities totaled CNY 344,703,376.27, a slight decrease from CNY 353,187,484.16 in the same period last year[40]. Research and Development - Research and development expenses totaled ¥17,404,587.43, accounting for 26.82% of operating revenue, an increase of 4.56 percentage points[10]. - R&D expenses rose to CNY 17,404,587.43, reflecting an 18.4% increase from CNY 14,695,524.66 in Q1 2022[31]. Operational Challenges - The company faced operational challenges in January due to the COVID-19 pandemic, impacting nearly half of the sales period[10]. - The company recognized share-based payment expenses of ¥11,972,800, which affected the net profit calculation[10]. Other Information - Non-recurring gains included government subsidies amounting to ¥386,590.80 and other income totaling ¥2,601,667.70[11]. - The company has not disclosed any new product developments or market expansion strategies in the current report[19]. - The company’s financial expenses showed a decrease, with interest expenses at CNY 16,077.44 compared to CNY 20,901.84 in Q1 2022[31]. - Other comprehensive income after tax for Q1 2023 was CNY 35,493.45, down from CNY 173,909.15 in the same quarter last year[34]. - The company paid CNY 24,907,230.46 in employee compensation, an increase of 15.5% from CNY 21,679,355.16 in the previous year[39]. - The company’s short-term borrowings and other liabilities were not detailed in the provided data, indicating a focus on asset management and liquidity[26]. - The top ten shareholders include significant holdings by private equity funds, indicating strong institutional interest in the company[21].